Tribunal Partially Allows Appeals on Transfer Pricing & Disallowances

The Tribunal partly allowed the appeals for the assessment years 2012-13, 2008-09, and 2013-14. The adjustments on transfer pricing and disallowances under section 37(1) were deleted or sent back for verification, while the jurisdictional and penalty-related grounds were dismissed.

---

---

Issues Involved:

1. Transfer Pricing Adjustments on import of APIs.
2. Recovery of cost of APIs and Bioequivalence studies under Contract Development Services.
3. Disallowance under section 37(1) of the Income Tax Act for payments to Doctors.
4. Jurisdiction of Transfer Pricing Officer (TPO).
5. Initiation of penalty proceedings under section 271(1)(c) of the Income Tax Act.

Issue-wise Detailed Analysis:

1. Transfer Pricing Adjustments on import of APIs:

The assessee, a subsidiary of Novartis Holding-AG, Switzerland, engaged in manufacturing and trading of Active Pharmaceutical Ingredients (APIs) and Finished Drugs Formulation (FDFs), imported 17 APIs from its Associated Enterprises (AEs). The Transactional Net Margin Method (TNMM) was used to benchmark these transactions. The TPO accepted the prices for 15 APIs but applied the Comparable Uncontrolled Price (CUP) method for two APIs, resulting in an adjustment of Rs. 17,97,82,202/-. The assessee argued that import and export transactions were inter-linked and should not be treated separately. The Tribunal found that the international transactions of importing APIs and exporting FDFs were within group companies and interlinked, thus rejecting the TPO's method of cherry-picking two APIs for CUP application. The adjustment made on the import cost of APIs was deleted.

2. Recovery of cost of APIs and Bioequivalence studies under Contract Development Services:

The TPO made an adjustment of Rs. 24,89,43,950/- by applying a mark-up of 34.45% on recoveries of costs of APIs and bioequivalence studies, treating them as part of Contract Development Services. The assessee contended that these were pass-through costs recovered on an actual basis without any mark-up. The Tribunal accepted the alternative plea that if these costs were included in the segment revenue and cost, the revised margin of 18.03% would still meet the arm's length test compared to the average margin of comparable companies at 13.08%. Consequently, the adjustment was deleted.

3. Disallowance under section 37(1) of the Income Tax Act for payments to Doctors:

The Assessing Officer disallowed Rs. 1,30,04,803/- under section 37(1) for payments purportedly made to Doctors, referring to the Indian Medical Council (Professional Conduct Etiquette and Ethics) Regulations 2002 and CBDT Circular 5/2012. The assessee argued that the expenses were incurred for conducting seminars and were not in violation of MCI guidelines, which apply to medical practitioners and not pharmaceutical companies. The Tribunal, relying on various judicial precedents, held that MCI regulations do not apply to pharmaceutical companies, and restored the issue to the Assessing Officer for verification of the expenditure.

4. Jurisdiction of Transfer Pricing Officer (TPO):

The assessee raised legal grounds challenging the jurisdiction of the TPO. However, these grounds were not pressed by the assessee and were dismissed accordingly.

5. Initiation of penalty proceedings under section 271(1)(c) of the Income Tax Act:

The assessee challenged the initiation of penalty proceedings under section 271(1)(c). The Tribunal found the challenge premature at this stage and dismissed this ground.

Summary of Judgments:

The Tribunal partly allowed the appeals for the assessment years 2012-13, 2008-09, and 2013-14. The key adjustments on transfer pricing and disallowances under section 37(1) were deleted or sent back for verification, while the jurisdictional and penalty-related grounds were dismissed.

---